chartexchange

Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission

GlobeNewswire Inc. | Nov 17, 2026 9:25 AM EST

TORONTO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the European Commission (EC) has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS).

Read original article